Follow
Aitziber Buqué Martínez
Aitziber Buqué Martínez
Weill Cornell Medical College - Radiation Oncology - Galluzzi Lab
Verified email at med.cornell.edu
Title
Cited by
Cited by
Year
Immunogenic cell death in cancer and infectious disease
L Galluzzi, A Buqué, O Kepp, L Zitvogel, G Kroemer
Nature Reviews Immunology 17 (2), 97-111, 2017
17682017
Immunological effects of conventional chemotherapy and targeted anticancer agents
L Galluzzi, A Buque, O Kepp, L Zitvogel, G Kroemer
Cancer cell 28 (6), 690-714, 2015
11882015
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
7302014
Classification of current anticancer immunotherapies
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ...
Oncotarget 5 (24), 12472, 2014
4842014
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ...
Journal for immunotherapy of cancer 8 (1), 2020
4792020
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
L Galluzzi, J Humeau, A Buqué, L Zitvogel, G Kroemer
Nature reviews Clinical oncology 17 (12), 725-741, 2020
4312020
Caloric restriction mimetics enhance anticancer immunosurveillance
F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ...
Cancer cell 30 (1), 147-160, 2016
4182016
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
T Yamazaki, A Kirchmair, AI Sato, A Buque, M Rybstein, G Petroni, N Bloy, ...
Nature Immunology 21 (10), 1160-1171, 2020
1532020
Trial Watch: Peptide-based anticancer vaccines
J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ...
Oncoimmunology 4 (4), e974411, 2015
1302015
Trial Watch—Oncolytic viruses and cancer therapy
J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ...
Oncoimmunology 5 (2), e1117740, 2016
1232016
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
K Iribarren, N Bloy, A Buqué, I Cremer, A Eggermont, WH Fridman, ...
1132015
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
A Buqué, N Bloy, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008814, 2015
1012015
eIF2α phosphorylation as a biomarker of immunogenic cell death
O Kepp, M Semeraro, JM Bravo-San Pedro, N Bloy, A Buqué, X Huang, ...
Seminars in cancer biology 33, 86-92, 2015
972015
Immunomodulation by targeted anticancer agents
G Petroni, A Buqué, L Zitvogel, G Kroemer, L Galluzzi
Cancer Cell 39 (3), 310-345, 2021
942021
Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients
ME Rodriguez-Ruiz, A Buqué, M Hensler, J Chen, N Bloy, G Petroni, ...
Oncoimmunology 8 (11), e1655964, 2019
792019
Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance
N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ...
Immunological reviews 280 (1), 165-174, 2017
722017
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
E Vacchelli, N Bloy, F Aranda, A Buqué, I Cremer, S Demaria, ...
Oncoimmunology 5 (9), e1214790, 2016
712016
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
A Buqué, N Bloy, M Perez-Lanzón, K Iribarren, J Humeau, JG Pol, ...
Nature communications 11 (1), 3819, 2020
632020
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
T Yamazaki, A Buqué, TD Ames, L Galluzzi
Oncoimmunology 9 (1), 1721810, 2020
582020
Modeling tumor immunology and immunotherapy in mice
A Buqué, L Galluzzi
Trends in Cancer 4 (9), 599-601, 2018
582018
The system can't perform the operation now. Try again later.
Articles 1–20